Company Focus

Bayer

Latest Bayer News

Formycon’s Eylea biosimilar wins EC approval
Biotechnology
Germany’s Formycon and its licensing partner Klinge Biopharma have announced that the European Commission (EC) has granted central marketing authorization for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names Ahzantive and Baiama.   20 January 2025


Latest News & Features of interest to Bayer

Latest In Brief for Bayer

Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jeraygo (aprocitentan) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately controlled by at least three other medicines (also known as resistant hypertension).   17 January 2025

Latest Ones To Watch News of interest to Bayer

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered under Medicare Part D for price negotiations. US antiviral giant Gilead Sciences is broadening its therapeutics focus with a deal for LEO Pharma’s small molecule oral STAT6 program in the area of inflammatory diseases.US healthcare giant Johnson & Johnson announced its planned $14.6 billion acquisition of Intra-Cellular Therapies, along with its already marketed CNS drug Caplyta. USA-based Keros Therapeutics revealed it is termination another Phase II study of its pulmonary arterial hypertension (PAH) candidate cibotercept. Also, Italy’s Newron Pharmaceuticals out-licensed its CNS drug evenamide to South Korea’s Myung In Pharma, having just recently licensed the drug to EA Pharma, a unit of Japan’s Eisai.   19 January 2025

More in M&A >


Ones to Watch Companies of interest to Bayer

Reset all filters
Refine Search